3164 — Genmont Biotech Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesBalancedMicro CapFalling Star

Annual income statement for Genmont Biotech, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	325	428	369	318	385
Cost of Revenue
Gross Profit	215	299	257	211	238
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	247	303	307	311	345
Operating Profit	78.5	125	62	6.99	40.6
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	76.8	139	66.3	28.2	64.7
Provision for Income Taxes
Net Income After Taxes	60.2	110	47.5	22.4	47.8
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	60.9	113	57	33	57.3
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	60.9	113	57	33	57.3
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.623	1.27	0.658	0.378	0.66
Dividends per Share